European Journal of Heart Failure最新文献

{"title":"Beyond quadruple therapy for heart failure with reduced ejection fraction: where do additional medical therapies fit?","authors":"Stephen J Greene, Javed Butler, Gregg C Fonarow","doi":"10.1093/ejhf/xuag053","DOIUrl":"10.1093/ejhf/xuag053","url":null,"abstract":"","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":" ","pages":"444-447"},"PeriodicalIF":10.3,"publicationDate":"2026-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147300522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genitourinary tract infections and SGLT2 inhibitors in heart failure: an EMPEROR-Pooled analysis.","authors":"João Pedro Ferreira, Faiez Zannad, Javed Butler, Gerasimos Filippatos, Francisco Vasques-Nóvoa, Pedro Marques, João Sérgio Neves, Stefan D Anker, Milton Packer","doi":"10.1093/ejhf/xuag054","DOIUrl":"10.1093/ejhf/xuag054","url":null,"abstract":"<p><strong>Aims: </strong>Sodium glucose co-transporter-2 inhibitors (SGLT2i) improve outcomes of patients with heart failure (HF). Urinary tract infections (UTI) are relatively common in HF, and their occurrence has been associated with an increased mortality risk. The use of SGLT2i has been associated with the occurrence of UTIs and mycotic genitourinary infections (MGI) which are a major cause of treatment discontinuation. This study aimed to study genitourinary infections in men and women with HF, their association with outcomes, and the impact of empagliflozin.</p><p><strong>Methods: </strong>Analysis of EMPEROR-Pooled including a total of 9718 patients across the spectrum of ejection fraction. Descriptive statistics, Cox and time-varying survival models were used. The median follow-up time was 21 months.</p><p><strong>Results: </strong>Throughout follow-up, 757 (7.8%) patients experienced a lower UTI, 60 (0.6%) MGI, and 41 pyelonephritis/urosepsis (0.4%). Genitourinary infections were more frequent in women than in men. Compared to patients without UTI/MGI, those with pyelonephritis/urosepsis were older and had higher comorbidity burden, whereas those with MGI were younger and had a higher prevalence of diabetes and obesity. Compared to placebo, empagliflozin was associated with a higher risk of lower UTI and MGI, particularly balanitis in men, but not pyelonephritis/urosepsis. The risk of death increased after UTI, but not after MGI. The effect of empagliflozin versus placebo on the composite of HF hospitalization or cardiovascular death was not modified by the occurrence of genitourinary infections.</p><p><strong>Conclusions: </strong>Lower UTIs were relatively frequent in HF patients, whereas MGI and pyelonephritis/urosepsis were infrequent. SGLT2i increased the risk of lower UTI and MGI. Although UTI, but not MGI, were associated with a higher subsequent risk of death, the clinical benefits of SGLT2i were preserved regardless of genitourinary infection occurrence.</p>","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":" ","pages":"448-457"},"PeriodicalIF":10.3,"publicationDate":"2026-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147320999","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sodium-glucose cotransporter-2 inhibitors in heart failure. How durable is the decongestive effect?","authors":"Mateusz Guzik, Robert Zymliński, Jan Biegus","doi":"10.1093/ejhf/xuaf019","DOIUrl":"10.1093/ejhf/xuaf019","url":null,"abstract":"","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":" ","pages":"422-424"},"PeriodicalIF":10.3,"publicationDate":"2026-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147343162","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of sodium-glucose cotransporter 2 inhibitors on cardiac metabolism, assessed by phosphorus magnetic resonance spectroscopy, in patients with heart failure.","authors":"Paweł Rubiś, Ewa Dziewięcka, Robert Banyś, Monika Lisiecka, Michał Świeczewski, Małgorzata Urbańczyk-Zawadzka, Joanna Szachowicz-Jaworska, Sylwia Wiśniowska-Śmiałek, Mateusz Winiarczyk, Katarzyna Graczyk, Natalia Przytuła, Agnieszka Stępień-Wroniecka, John G F Cleland","doi":"10.1093/ejhf/xuag026","DOIUrl":"10.1093/ejhf/xuag026","url":null,"abstract":"","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":" ","pages":"433-436"},"PeriodicalIF":10.3,"publicationDate":"2026-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147343125","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MRA-induced eGFR decline-causes, consequences, and context.","authors":"Nicolas Girerd, Lars H Lund","doi":"10.1093/ejhf/xuag096","DOIUrl":"10.1093/ejhf/xuag096","url":null,"abstract":"","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":" ","pages":"535-537"},"PeriodicalIF":10.3,"publicationDate":"2026-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148596865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"What's new in heart failure? June 2026.","authors":"Philipp Markwirth, Julian Hoevelmann, Mert Tokcan, Bernhard Haring","doi":"10.1093/ejhf/xuag204","DOIUrl":"10.1093/ejhf/xuag204","url":null,"abstract":"","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":" ","pages":"343-346"},"PeriodicalIF":10.3,"publicationDate":"2026-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148314947","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Phenotype-specific prognostic implications of pulse pressure in heart failure","authors":"Misato Chimura,Kieran F Docherty,Alasdair D Henderson,Akshay S Desai,Michel Komajda,Milton Packer,Marc A Pfeffer,Bertram Pitt,John R Teerlink,Muthiah Vaduganathan,Faiez Zannad,Michael R Zile,Pardeep S Jhund,Scott D Solomon,John J V McMurray","doi":"10.1093/ejhf/xuag292","DOIUrl":"https://doi.org/10.1093/ejhf/xuag292","url":null,"abstract":"Abstract Aims The prognostic significance of pulse pressure (PP) differs across HF phenotypes, but its relevance in HFmrEF remains uncertain. We evaluated associations between PP and clinical outcomes across HF phenotypes and assessed whether PP provides prognostic information beyond SBP. Methods and results We performed a patient-level pooled analysis of 13 randomised HF trials including 35,550 patients with HFrEF, 6,484 with HFmrEF, and 19,173 with HFpEF. PP–outcome associations were assessed using Cox models for quartiles and Poisson regression with restricted cubic splines for continuous PP. Across HF phenotypes, patients with higher PP were older, more frequently female, and had higher LVEF and greater adiposity. In HFrEF, PP was inversely associated with first HF hospitalization or cardiovascular death, with the lowest event rate in the highest PP quartile (&amp;gt;56 mmHg; 13.3 per 100 person-years [95% CI, 12.8–13.8]) and the highest event rate in the lowest quartile (&amp;lt;40 mmHg; 18.2 [17.5–18.9]). In contrast, HFpEF demonstrated a J-shaped relationship, with the lowest event rate in the second quartile (48–56 mmHg; 6.8 [6.4–7.3]) and the highest in the fourth quartile (&amp;gt; 66 mmHg; 9.7 [9.1–10.3]). HFmrEF exhibited a similar J-shaped association, closely paralleling HFpEF. PP improved model fit beyond SBP, but the incremental improvement in discrimination was small and largely limited to HF hospitalization-related outcomes in HFpEF. Conclusions PP has phenotype-specific prognostic implications in HF. Low PP identifies higher risk in HFrEF, whereas high PP identifies higher risk in HFpEF and HFmrEF. PP may support phenotype-specific risk stratification.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"51 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2026-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148923192","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to: Clinical and cardiac magnetic resonance phenotype of probable viral vs probable immune-mediated acute myocarditis.","authors":"","doi":"10.1093/ejhf/xuag284","DOIUrl":"https://doi.org/10.1093/ejhf/xuag284","url":null,"abstract":"","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":" ","pages":""},"PeriodicalIF":10.3,"publicationDate":"2026-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148928581","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Target-dose vs below-target-dose lisinopril and fosinopril in HFrEF with advanced CKD.","authors":"Amiya A Ahmed, Frederick Lu, Hans J Moore, Tariq Ahmad, Wen-Chih Wu, Samir S Patel, Phillip H Lam, Charity J Morgan, Stefan D Anker, Paul A Heidenreich, Gregg C Fonarow, Ali Ahmed","doi":"10.1093/ejhf/xuag257","DOIUrl":"https://doi.org/10.1093/ejhf/xuag257","url":null,"abstract":"","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":" ","pages":""},"PeriodicalIF":10.3,"publicationDate":"2026-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148910106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of Vericiguat by Background Guideline-Directed Medical Therapy in the VICTOR Trial.","authors":"Justin A Ezekowitz, Javed Butler, Derek Cyr, Kevin J Anstrom, Irina Barash, Marc P Bonaca, Stefano Corda, Carolyn S P Lam, Eldrin F Lewis, JoAnn Lindenfeld, Ciaran J McMullan, Robert J Mentz, Christopher M O'Connor, Piotr Ponikowski, Yogesh N V Reddy, Giuseppe Rosano, Clara Saldarriaga, Michele Senni, Stefan Störk, James E Udelson, Adriaan A Voors, Henrik Wiggers, Faiez Zannad","doi":"10.1093/ejhf/xuag294","DOIUrl":"https://doi.org/10.1093/ejhf/xuag294","url":null,"abstract":"<p><strong>Background and aims: </strong>It is uncertain whether the effect of vericiguat varies across levels of background guideline-directed medical therapy (GDMT) in heart failure with reduced ejection fraction (HFrEF).</p><p><strong>Methods: </strong>We conducted an exploratory analysis of VICTOR, which enrolled 6105 ambulatory patients with HFrEF without recent worsening. GDMT exposure was classified as basic adherence (on vs. off), indication-corrected adherence (accounting for eligibility and contraindications), and dose-corrected adherence (≥50% target dose). A GDMT intensity score was computed from class-specific dose levels. The primary endpoint was the composite of cardiovascular death or first HF hospitalization. Stratified Cox proportional hazards regression models estimated adjusted hazard ratios for vericiguat versus placebo within GDMT strata, with treatment-by-GDMT interaction test.</p><p><strong>Results: </strong>Baseline contemporary GDMT use was high (any ARNI/ACE/ARB 93.9%, ARNI 56%, SGLT2i 59%, MRA 78%, beta-blocker 94%). Basic adherence: adjusted HRs for the primary endpoint were similar whether or not patients were on ACEi/ARB, ARNI, any RAS inhibitor, beta-blocker, or SGLT2i. Dose-corrected adherence: adjusted HRs favored vericiguat in ARNI target-dose users (0.73; 0.57-0.93) and in any RAS target-dose users (0.77; 0.64-0.93), with lower risk on vericiguat in patients not meeting MRA target dose (0.67; 0.48-0.95); interaction P-values were nominally significant. The GDMT intensity score showed no significant interaction with treatment. Patterns for cardiovascular death and all-cause death paralleled the primary endpoint.</p><p><strong>Conclusions: </strong>In ambulatory patients with HFrEF receiving contemporary GDMT, we did not find convincing evidence that the neutral effect of vericiguat on cardiovascular death or first HF hospitalization was modified by GDMT class, dose attainment, or overall intensity, in a cohort with very high background GDMT use and limited power for interaction testing. These exploratory, hypothesis-generating findings do not establish independent efficacy or pathway additivity for vericiguat and should not be used to guide clinical recommendations regarding GDMT sequencing.</p>","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":" ","pages":""},"PeriodicalIF":10.3,"publicationDate":"2026-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148904597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}